Recognizing senescent vascular smooth muscle cells in diabetic atherosclerosis: biomarkers, transcriptomic signatures, and methodological validity
- 1The First Affiliated Hospital, College of Clinical Medicine, Henan University of Science and Technology
- 2Luoyang Key Laboratory of Cardiovascular Science, The First Affiliated Hospital, Henan University of Science and Technology
Abstract
Diabetic atherosclerosis represents the most severe macrovascular complication of diabetes mellitus and a major contributor to global morbidity and mortality. Senescence of vascular smooth muscle cells (VSMCs) has been increasingly recognized as a central mechanism driving plaque formation, progression, and instability under diabetic conditions. Yet identifying senescent VSMCs reliably remains difficult: available biomarkers lack specificity, transcriptomic signatures vary considerably across studies, and no consensus has emerged on how senescence should be verified methodologically. This review consolidates current knowledge on senescent VSMC identification in diabetic atherosclerosis. We begin with the pathobiological routes through which hyperglycemia drives VSMC senescence, including oxidative stress, DNA damage, mitochondrial dysfunction, and metabolic reprogramming. We then present a multidimensional classification of senescence-associated biomarkers, spanning cell cycle regulators, senescence-associated β-galactosidase (SA-β-gal), telomere-related markers, the senescence-associated secretory phenotype (SASP), calcification markers, and emerging non-coding RNA signatures, and assess the applicability and shortcomings of each. Transcriptomic signatures derived from single-cell RNA sequencing, spatial transcriptomics, and flow cytometry are then integrated to map the heterogeneity of senescent VSMC subpopulations and their functional roles within atherosclerotic plaques. We next appraise the methodological validity of existing detection strategies, comparing in vitro high-glucose models, in vivo diabetic animal models, and clinical specimens, and trace the sources of inter-study inconsistency, including spatial heterogeneity, cross-sectional designs, and the absence of standardized protocols. Finally, we outline a stepwise identification pipeline extending from molecular markers to functional validation and multi-omics integration, and consider future prospects such as senolytic therapies and targeted delivery systems. By providing this methodological reference, we hope to support both basic research and clinical translation and to push the field toward more precise, standardized identification of senescent VSMCs.
Related
- Inflammatory biomarkers show sex-specific associations with cardiometabolic disease and coronary atherosclerosis as assessed by coronary CT angiography
- Transcriptomic Assessment of PD-L1 (CD274) in NSCLC: Biological Significance, Clinical Relevance, and Methodological Challenges
- Single-cell profiling of human plaques reveals cellular and molecular signatures of symptomatic atherosclerosis
- A whole-blood transcriptomic analysis of shared molecular mechanisms between subclinical atherosclerosis and hypothyroidism in women
- CT-Derived Adipose Tissue Biomarkers in Coronary and Carotid Atherosclerosis: A Systematic Review of Dual-Energy, Spectral, and Photon-Counting CT
BibTeX
@article{yang2026recognizing,
title = {{Recognizing senescent vascular smooth muscle cells in diabetic atherosclerosis: biomarkers, transcriptomic signatures, and methodological validity}},
author = {Xiaoxu Yang and Di Zhao},
journal = {Frontiers in Endocrinology},
year = {2026},
month = oct,
doi = {10.3389/fendo.2026.1997338},
url = {https://www.frontiersin.org/articles/10.3389/fendo.2026.1997338/full},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - Recognizing senescent vascular smooth muscle cells in diabetic atherosclerosis: biomarkers, transcriptomic signatures, and methodological validity
AU - Xiaoxu Yang
AU - Di Zhao
PY - 2026
DA - 2026/10/30
JO - Frontiers in Endocrinology
DO - 10.3389/fendo.2026.1997338
UR - https://www.frontiersin.org/articles/10.3389/fendo.2026.1997338/full
AB - Diabetic atherosclerosis represents the most severe macrovascular complication of diabetes mellitus and a major contributor to global morbidity and mortality. Senescence of vascular smooth muscle cells (VSMCs) has been increasingly recognized as a central mechanism driving plaque formation, progression, and instability under diabetic conditions. Yet identifying senescent VSMCs reliably remains difficult: available biomarkers lack specificity, transcriptomic signatures vary considerably across studies, and no consensus has emerged on how senescence should be verified methodologically. This review consolidates current knowledge on senescent VSMC identification in diabetic atherosclerosis. We begin with the pathobiological routes through which hyperglycemia drives VSMC senescence, including oxidative stress, DNA damage, mitochondrial dysfunction, and metabolic reprogramming. We then present a multidimensional classification of senescence-associated biomarkers, spanning cell cycle regulators, senescence-associated β-galactosidase (SA-β-gal), telomere-related markers, the senescence-associated secretory phenotype (SASP), calcification markers, and emerging non-coding RNA signatures, and assess the applicability and shortcomings of each. Transcriptomic signatures derived from single-cell RNA sequencing, spatial transcriptomics, and flow cytometry are then integrated to map the heterogeneity of senescent VSMC subpopulations and their functional roles within atherosclerotic plaques. We next appraise the methodological validity of existing detection strategies, comparing in vitro high-glucose models, in vivo diabetic animal models, and clinical specimens, and trace the sources of inter-study inconsistency, including spatial heterogeneity, cross-sectional designs, and the absence of standardized protocols. Finally, we outline a stepwise identification pipeline extending from molecular markers to functional validation and multi-omics integration, and consider future prospects such as senolytic therapies and targeted delivery systems. By providing this methodological reference, we hope to support both basic research and clinical translation and to push the field toward more precise, standardized identification of senescent VSMCs.
SN - 1664-2392
ER -